Tempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 250,000 Shares of Company Stock

Posted by Brian Himes on Sep 25th, 2026

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) CEO Eric Lefkofsky sold 250,000 shares of the company’s stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $77.47, for a total value of $19,367,500.00. Following the completion of the transaction, the chief executive officer directly owned 100,000 shares of the company’s stock, valued at $7,747,000. The trade was a 71.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Trading Up 7.4%

Shares of NASDAQ:TEM opened at $82.24 on Friday. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The business’s 50 day moving average price is $58.96 and its 200-day moving average price is $53.65. The firm has a market capitalization of $14.84 billion, a price-to-earnings ratio of -57.11 and a beta of 3.72. Tempus AI, Inc. has a 1 year low of $40.77 and a 1 year high of $104.32.

Tempus AI (NASDAQ:TEM – Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. The business had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company’s revenue for the quarter was up 21.6% compared to the same quarter last year. During the same quarter last year, the business earned ($0.22) earnings per share. On average, equities research analysts forecast that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Institutional Trading of Tempus AI

A number of institutional investors and hedge funds have recently bought and sold shares of TEM. Main Management ETF Advisors LLC raised its holdings in Tempus AI by 1.0% during the fourth quarter. Main Management ETF Advisors LLC now owns 26,622 shares of the company’s stock worth $1,572,000 after purchasing an additional 272 shares in the last quarter. Arkadios Wealth Advisors boosted its holdings in shares of Tempus AI by 9.6% in the 1st quarter. Arkadios Wealth Advisors now owns 4,963 shares of the company’s stock valued at $224,000 after buying an additional 435 shares in the last quarter. EMC Capital Management purchased a new position in shares of Tempus AI in the 2nd quarter valued at $29,000. NewEdge Advisors LLC grew its position in shares of Tempus AI by 1.3% in the 1st quarter. NewEdge Advisors LLC now owns 42,996 shares of the company’s stock valued at $1,944,000 after buying an additional 536 shares during the last quarter. Finally, SteelPeak Wealth LLC raised its stake in Tempus AI by 6.2% during the 1st quarter. SteelPeak Wealth LLC now owns 9,245 shares of the company’s stock worth $418,000 after acquiring an additional 538 shares in the last quarter. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

Positive Sentiment: Tempus AI was included among AI-powered medical stocks recommended for consideration in the fourth quarter. The article points to AI adoption in precision medicine and drug development as long-term growth drivers for Tempus. Buy 3 AI-Powered Medical Stocks to Strengthen Your Portfolio in Q4
Positive Sentiment: Tempus AI also appeared in a list of artificial-intelligence stocks for investors to research, providing additional exposure to the company’s AI growth narrative. Top Artificial Intelligence Stocks To Research – September 23rd
Neutral Sentiment: A market-data report stated that short interest was 0 shares as of September 24, with a 0.0-day days-to-cover ratio. If accurate, this suggests little evidence of short-covering demand, although the figure may reflect a data-reporting issue. Tempus AI short-interest data
Negative Sentiment: CEO Eric Lefkofsky sold 250,000 shares for approximately $19.4 million, reducing his direct stake by 71.43%. The transaction occurred under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary bearish signal but still adds insider-selling pressure. Tempus AI CEO Form 4 filing
Negative Sentiment: Tempus AI’s chief accounting officer separately sold $529,650 of stock, adding to recent insider-selling concerns. Tempus AI Chief Accounting Officer Sells $529,650 of Stock

Analyst Upgrades and Downgrades

A number of research firms have weighed in on TEM. Piper Sandler raised shares of Tempus AI from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $56.00 to $76.00 in a research note on Tuesday, September 1st. HC Wainwright increased their price target on Tempus AI from $56.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, September 11th. UBS Group began coverage on shares of Tempus AI in a report on Wednesday, September 9th. They issued a “neutral” rating and a $70.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a research report on Friday, July 31st. Finally, Wall Street Zen raised shares of Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Eleven investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $69.63.

Check Out Our Latest Stock Report on Tempus AI

About Tempus AI

(Get Free Report)

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.